- Home
- CTOR vs APLT Comparison
CTOR vs APLT Comparison
Compare CTOR & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- APLT
- Stock Information
- Founded
- CTOR 2021
- APLT 2016
- Country
- CTOR United States
- APLT United States
- Employees
- CTOR N/A
- APLT N/A
- Industry
- CTOR
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- APLT Health Care
- Exchange
- CTOR NYSE
- APLT Nasdaq
- Market Cap
- CTOR 63.7M
- APLT 52.4M
- IPO Year
- CTOR N/A
- APLT 2019
- Fundamental
- Price
- CTOR $5.05
- APLT $0.32
- Analyst Decision
- CTOR Buy
- APLT Buy
- Analyst Count
- CTOR 2
- APLT 7
- Target Price
- CTOR $6.00
- APLT $6.10
- AVG Volume (30 Days)
- CTOR 3.1M
- APLT 2.2M
- Earning Date
- CTOR 08-11-2025
- APLT 08-06-2025
- Dividend Yield
- CTOR N/A
- APLT N/A
- EPS Growth
- CTOR N/A
- APLT N/A
- EPS
- CTOR N/A
- APLT N/A
- Revenue
- CTOR N/A
- APLT $265,000.00
- Revenue This Year
- CTOR N/A
- APLT $1,768.13
- Revenue Next Year
- CTOR N/A
- APLT $292.85
- P/E Ratio
- CTOR N/A
- APLT N/A
- Revenue Growth
- CTOR N/A
- APLT N/A
- 52 Week Low
- CTOR $0.55
- APLT $0.30
- 52 Week High
- CTOR $49.00
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- APLT 42.58
- Support Level
- CTOR N/A
- APLT $0.30
- Resistance Level
- CTOR N/A
- APLT $0.39
- Average True Range (ATR)
- CTOR 0.00
- APLT 0.03
- MACD
- CTOR 0.00
- APLT 0.00
- Stochastic Oscillator
- CTOR 0.00
- APLT 21.64
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.